Toward a unifying hypothesis in the development of alzheimer's disease

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 587-589

  Balin, Brian ^a   Abrams, J Todd ^b   Schrogie, John ^b  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; DOXYCYCLINE; MACROLIDE; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN FUNCTION; BRAIN INFECTION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; EDITORIAL; FOREBRAIN; GENOTYPE; HUMAN; MUCOSAL IMMUNITY; NEUROPATHOLOGY; NONHUMAN; SMELLING DISORDER;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC AGENTS; HUMANS;

EID: 82355172760     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00269.x     Document Type: Editorial

References (26)

1. Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis. Do current drugs work in Alzheimer's Disease? CNS Neurosci Ther 2010;16:235-245.
2. Arnold SE, Lee EB, Moberg PJ, Stutzbach L, Kazi H, Han L-Y, Lee VMY, Trojanowski JQ. Olfactory epithelium amyloid-β and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol 2010;67:462-469.
3. Devanand DP, Michaels-Marston KS, Liu X, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry 2000;157:1399-1405.
4. Doty RL. The olfactory vector hypothesis of neurodegenerative disease: Is it viable? Ann Neurol 2008;63:7-15.
5. Aleksandrova IY, Kuvichkin VV, Kashparov IA, et al. Increased level of beta-amyloid in the brain of bulbectomized mice. Biochemistry (Mosc) 2004;69:176-180.
6. Brunjes PC. Lessons from lesions - The effects of olfactory bulbectomy. Chem Senses 1992;17:729-763.
7. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: An update. Pharmcol Ther 1997;74:299-316.
8. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR. Brain structural alterations before mild cognitive impairment. Neurology 2007;68(16):1268-1273.
9. Miklossy J. Chronic inflammation and amyloidogenesis in Alzheimer's disease - Role of Spirochetes. J Alzheimers Dis 2008;13(4):381-91.
10. Gerard HC, Wildt KL, Whittum-Hudson JA, Lai Z, Ager J, Hudson AP. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb Pathog 2005;39:19-26.
11. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson Ap. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl) 1998;187(1):23-42.
12. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. The Alzheimer's Disease-associated amyloid β-Protein Is an antimicrobial peptide. PLoS ONE 2010;5(3):e9505.
13. Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996;55:1083-108.
14. Rasmussen SJ, Eckmann L, Quayle AJ, Shen L, Zhang YX, et al. Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest 1997;99:77-87.
15. Esiri M, Biddolph S, Morris C. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 1998;65(1):29-33.
16. Ando Y, Nakamura M, Kai H, Katsuragi S, Terazaki H, et al. A novel localized amyloidosis associated with lactoferrin in the cornea. Lab Invest 2002;82:757-766.
17. Araki-Sasaki K, Ando Y, Nakamura M, Kitagawa K, Ikemizu S, et al. Lactoferrin Glu561Asp facilitates secondary amyloidosis in the cornea. Br J Ophthalmol 2005;89:684-688.
18. Gerard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, Frey WH, 2nd, Bordayo EZ, Whittum-Hudson JA, Hudson AP. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol 2006;48(3):355-366.
19. Grayston JT, Aldous MB, Easton A, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 1993;168:1231-1235.
20. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-625.
21. Paltiel O, Kark JD, Leinonen M, Saikku P. High prevalence of antibodies to Chlamydia pneumoniae: Determinants of IgG seropositivity among Jerusalem residents. Epidemiol Infect 1995;114:465-473.
22. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 2004;25(4):419-429.
23. Hammond CJ, Little CS, Longo N, Procacci C, Appelt DM, Balin BJ. Antibiotic alters inflammation in the mouse brain during persistent Chlamydia pnemoniae infection. In: Alzheimer's disease: New advances, K. Igbal, B. Winblat and J. Avila, eds., Medimond, Bologna, Italy 2006; 295-299.
24. Loeb MB, Molloy D, Smieja M. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriat Soc 2004;52:381-387.
25. Balin BJ, Little CS, Hammond CJ, Appelt DM, Whittum-Hudson JA, Gérard HC, Hudson AP. Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J Alzheimers Dis 2008;13(4):371-380.
26. Herrup K. Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 2010;30(50):16755-16762.